Identification
- Summary
Beractant is a pulmonary surfactant used for the treatment and prevention of Respiratory Distress Syndrome (RDS) in premature infants.
- Brand Names
- Survanta
- Generic Name
- Beractant
- DrugBank Accession Number
- DB06761
- Background
Beractant is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as SP-B and SP-C. The final composition provides 25 mg/mL phospholipids (including 11.0-15.5 mg/mL disaturated phosphatidylcholine), 0.5-1.75 mg/mL triglycerides, 1.4-3.5 mg/mL free fatty acids, and less than 1.0 mg/mL protein. It is suspended in 0.9% sodium chloride solution, and heat-sterilized.
In anticipation of birth, endogenous lung surfactant is produced to lower the surface tension on alveolar surfaces and to stabilize the alveoli against collapse at resting transpulmonary pressures. However, in Respiratory Distress Syndrome, developmental deficiency of surfactant results collapse of the alveoli causing fast breathing, increased heart rate, apoxia, and sometimes death. Administration of lung surfactant remains the cornerstone of therapy in this condition that is currently the leading cause of death in preterm infants. In comparison to synthetic forms of surfacant, natural forms such as Beractant have been found to have a reduced incidence of pneumothorax and reduced mortality.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Beractant
- Beraksurf
- External IDs
- A 60386X
- A-60386X
- A60386X
Pharmacology
- Indication
Beractant is indicated for prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
In vitro, Beractant reproducibly lowers minimum surface tension to less than 8 dynes/cm as measured by the pulsating bubble surfactometer and Wilhelmy Surface Balance. In situ, it restores pulmonary compliance to excised rat lungs artificially made surfactant-deficient. In vivo, single doses improve lung pressure-volume measurements, lung compliance, and oxygenation in premature rabbits and sheep.
- Mechanism of action
Beractant replenishes lung surfactant and restores surface activity to the lungs by lowering surface tension on alveolar surfaces during respiration and stabilizing the alveoli against collapse at resting transpulmonary pressures.
- Absorption
Beractant is administered directly to the target organ, the lungs, where biophysical effects occur at the alveolar surface.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
In surfactant-deficient premature rabbits and lambs, alveolar clearance of radio-labelled lipid components of beractant is rapid. Most of the dose becomes lung-associated within hours of administration, and the lipids enter endogenous surfactant pathways of reutilization and recycling. Limited animal experiments have not found effects of beractant on endogenous surfactant metabolism.
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol Acebutolol may increase the bradycardic activities of Beractant. Alfentanil Alfentanil may increase the bradycardic activities of Beractant. Amiodarone Amiodarone may increase the bradycardic activities of Beractant. Amlodipine Amlodipine may increase the bradycardic activities of Beractant. Atenolol Atenolol may increase the bradycardic activities of Beractant. Bendroflumethiazide Bendroflumethiazide may increase the bradycardic activities of Beractant. Bepridil Bepridil may increase the bradycardic activities of Beractant. Betaxolol Betaxolol may increase the bradycardic activities of Beractant. Bisoprolol Bisoprolol may increase the bradycardic activities of Beractant. Bretylium Bretylium may increase the bradycardic activities of Beractant. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Calfactant unknown Q4K217VGA9 183325-78-2 Not applicable - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Survanta Suspension 25 mg / mL Endotracheal Abbvie 1993-12-31 Not applicable Canada 
Survanta Suspension 25 mg/1mL Endotracheal AbbVie Inc. 1991-07-01 Not applicable US 
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S866O45PIG
- CAS number
- 108778-82-1
References
- General References
- Bayat S, Porra L, Broche L, Albu G, Malaspinas I, Doras C, Strengell S, Petak F, Habre W: Effect of surfactant on regional lung function in an experimental model of respiratory distress syndrome in rabbit. J Appl Physiol (1985). 2015 Aug 1;119(3):290-8. doi: 10.1152/japplphysiol.00047.2015. Epub 2015 May 21. [Article]
- Speer CP, Sweet DG, Halliday HL: Surfactant therapy: past, present and future. Early Hum Dev. 2013 Jun;89 Suppl 1:S22-4. doi: 10.1016/S0378-3782(13)70008-2. [Article]
- Halliday HL: History of surfactant from 1980. Biol Neonate. 2005;87(4):317-22. Epub 2005 Jun 1. [Article]
- External Links
- KEGG Drug
- D03096
- PubChem Substance
- 347910369
- 46967
- ChEMBL
- CHEMBL1201624
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Beractant
- FDA label
- Download (3.16 MB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Basic Science Respiratory Distress Syndrome 1 4 Completed Treatment Respiratory Distress Syndrome, Newborn / Respiratory Failure 1 4 Terminated Treatment Infants, Premature / Patent Ductus Arteriosus (PDA) / Respiratory Distress Syndrome 1 4 Unknown Status Prevention Chronic Lung Disease of Prematurity / Respiratory Distress Syndrome 1 3 Terminated Treatment Newborn Infants / Respiratory Distress Syndrome / Respiratory Insufficiency 1 2, 3 Completed Treatment Chronic Lung Disease of Prematurity / Infants, Premature / Low Birth Weight Infants / Newborn Infants / Small for Gestational Age Infants 1 2, 3 Completed Treatment Respiratory Distress Syndrome 1 2, 3 Unknown Status Treatment Respiratory Distress Syndrome 1 1, 2 Completed Treatment Respiratory Distress Syndrome, Newborn 1 Not Available Completed Treatment Poor Peripheral Perfusion 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for suspension Endotracheal 45 mg/ml Suspension Endotracheal 80 MG/ML Suspension Endotracheal 142 mg/8ml Suspension Endotracheal 25 mg / mL Suspension Endotracheal 25 mg/1mL Suspension Endotracheal 25 mg Suspension Endotracheal Suspension Endotracheal 1 ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at September 14, 2010 16:21 / Updated at October 02, 2023 21:58